Thyroid dysfunction is not influencing serum asprosin levels in patients with retinopathy.
Keywords:
Retinopathy, Asprosin, TSH, T3 and T4Abstract
Background: Thyroid hormones, namely triiodothyronine (T3) and thyroxin (T4) and the major regulatory hormones of metabolic processes that impact the metabolism of carbohydrates, lipids, and proteins. Asprosin is a novel glucogenic hormone that triggers the liver to release glucose into the bloodstream; thereby, this hormone is probably affected by any thyroid dysfunction.
Objective: The current study aims to delineate whether abnormal levels of thyroid hormones, namely T3 and T4, have a significant association with asprosin levels in patients with retinopathy.
Methods: In the present case-control study, we employed 83 participants distributed as 56 patients with retinopathy and 27 healthy controls. We measured T3, T4, asprosin, glycated hemoglobin (HBA1c), and fasting blood sugar (FBS).
Results: There is no significant association between asprosin and low levels of T3 and T4 in patients with retinopathy. Decreased T3 and T4 levels were significantly (p > 0.05) associated with an increased probability of developing retinopathy. No significant changes in the serum asprosin level in patients with retinopathy.
Conclusion: Asprosin hormone is probably not involved in the pathophysiology of retinopathy, and the impaired T3 and T4 in patients with retinopathy were not associated with asprosin levels
Downloads
References
Abdul Jaleel, A. K., A. F. Almulla, H. A. Alnaji, M. R. Mansor and A. Abbas Abo Algon (2022). "Diabetes Mellitus and Non-Proliferative Diabetic Retinopathy Are Accompanied by Increase Pro-Inflammatory Conditions Indicated by a High Blood-Derived Levels of Monocyte Chemoattractant Protein-1 and Interleukin-8." JMERC 14(2): 203-210.
Atli, H., E. Onalan, B. Yakar, T. Kaymaz, D. Duzenci, K. Karakulak, E. Dönder, M. Gürsu and R. Dayanan (2022). "The relationship of serum asprosin level with diabetic and non-diabetic retinopathy." European Review for Medical and Pharmacological Sciences 26: 2117-2123.
Atlı, H., E. Onalan, B. Yakar, T. Kaymaz, D. Duzenci, K. Karakulak, E. Dönder, M. F. Gürsu and R. Dayanan (2022). "The relationship of serum asprosin level with diabetic and non-diabetic retinopathy." Eur Rev Med Pharmacol Sci 26(6): 2117-2123.
Bahi, L., A. Garnier, D. Fortin, B. Serrurier, V. Veksler, A. Bigard and R. Ventura‐Clapier (2005). "Differential effects of thyroid hormones on energy metabolism of rat slow‐and fast‐twitch muscles." Journal of cellular physiology 203(3): 589-598.
Bhadel, P., S. Shrestha, B. Sapkota, J. Y. Li and H. Tao (2020). "Asprosin and type 2 diabetes mellitus: a novel potential therapeutic implication." J Biol Regul Homeost Agents 34(1).
Cai, Y., M. M. Manio, G. P. Leung, A. Xu, E. H. Tang and P. M. Vanhoutte (2015). "Thyroid hormone affects both endothelial and vascular smooth muscle cells in rat arteries." European journal of pharmacology 747: 18-28.
Carmona-Cortés, J., I. Rodríguez-Gómez, R. Wangensteen, I. Banegas, Á. M. García-Lora, A. Quesada, A. Osuna and F. Vargas (2014). "Effect of thyroid hormone–nitric oxide interaction on tumor growth, angiogenesis, and aminopeptidase activity in mice." Tumor Biology 35(6): 5519-5526.
Dimitriadis, G., P. Mitrou, V. Lambadiari, E. Boutati, E. Maratou, D. B. Panagiotakos, E. Koukkou, M. Tzanela, N. Thalassinos and S. A. Raptis (2006). "Insulin action in adipose tissue and muscle in hypothyroidism." The Journal of Clinical Endocrinology & Metabolism 91(12): 4930-4937.
Dumitrescu, A. M., X.-H. Liao, M. S. Y. Abdullah, J. Lado-Abeal, F. A. Majed, L. C. Moeller, G. Boran, L. Schomburg, R. E. Weiss and S. Refetoff (2005). "Mutations in SECISBP2 result in abnormal thyroid hormone metabolism." Nature Genetics 37(11): 1247-1252.
Dumitrescu, A. M., X.-H. Liao, T. B. Best, K. Brockmann and S. Refetoff (2004). "A Novel Syndrome Combining Thyroid and Neurological Abnormalities Is Associated with Mutations in a Monocarboxylate Transporter Gene." The American Journal of Human Genetics 74(1): 168-175.
Duntas, L. H. and G. Brenta (2018). "A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism." Frontiers in Endocrinology 9.
Fasshauer, M. and M. Blüher (2015). "Adipokines in health and disease." Trends in Pharmacological Sciences 36(7): 461-470.
Jung, U. J. and M. S. Choi (2014). "Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease." Int J Mol Sci 15(4): 6184-6223.
Kocaturk, T., K. Ergin, G. Cesur, G. E. Evlicoglu and H. Cakmak (2016). "The effect of methimazole-induced postnatal hypothyroidism on the retinal maturation and on the Sirtuin 2 level." Cutan Ocul Toxicol 35(1): 36-40.
Li, X., M. Liao, R. Shen, L. Zhang, H. Hu, J. Wu, X. Wang, H. Qu, S. Guo, M. Long and H. Zheng (2018). "Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases." Mediators Inflamm 2018: 7375294.
Liu, X., N. Zheng, Y.-N. Shi, J. Yuan and L. Li (2014). "Thyroid hormone induced angiogenesis through the integrin αvβ3/protein kinase D/histone deacetylase 5 signaling pathway." Journal of Molecular Endocrinology 52(3): 245-254.
Mancuso, P. (2016). "The role of adipokines in chronic inflammation." Immunotargets Ther 5: 47-56.
Maratou, E., D. J. Hadjidakis, A. Kollias, K. Tsegka, M. Peppa, M. Alevizaki, P. Mitrou, V. Lambadiari, E. Boutati and D. Nikzas (2009). "Studies of insulin resistance in patients with clinical and subclinical hypothyroidism." European journal of endocrinology 160(5): 785.
Martino, E., H. Seo, A. Lernmark and S. Refetoff (1980). "Ontogenetic patterns of thyrotropin-releasing hormone-like material in rat hypothalamus, pancreas, and retina: selective effect of light deprivation." Proc Natl Acad Sci U S A 77(7): 4345-4348.
Mazur-Bialy, A. I. (2021). "Asprosin-A Fasting-Induced, Glucogenic, and Orexigenic Adipokine as a New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature." Nutrients 13(2).
Mendoza, A. and A. N. Hollenberg (2017). "New insights into thyroid hormone action." Pharmacol Ther 173: 135-145.
Morreale de Escobar, G., M. J. Obregon and F. Escobar del Rey (2004). "Role of thyroid hormone during early brain development." European Journal of Endocrinology Eur J Endocrinol 151(Suppl_3): U25-U37.
Ouchi, N., J. L. Parker, J. J. Lugus and K. Walsh (2011). "Adipokines in inflammation and metabolic disease." Nature Reviews Immunology 11(2): 85-97.
Ovali, M. A. and I. Bozgeyik (2022). "Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the FBN1 Gene, in Health and Disease." Molecular Syndromology: 1-9.
Popescu, T. and M. Moţa (2009). "Dyslipidemia and hypertension in patients with type 2 diabetes and retinopathy." Rom J Intern Med 47(3): 235-241.
Qi, Q., Q.-M. Zhang, C.-J. Li, R.-N. Dong, J.-J. Li, J.-Y. Shi, D.-M. Yu and J.-Y. Zhang (2017). "Association of thyroid-stimulating hormone levels with microvascular complications in type 2 diabetes patients." Medical science monitor: international medical journal of experimental and clinical research 23: 2715.
Ramis, J. N., C. F. Artigas, M. A. A. Santiago, F. J. V. Mañes, R. S. Canonge and L. M. Comas (2012). "Is there a relationship between TSH levels and diabetic retinopathy in the Caucasian population?" Diabetes Research and Clinical Practice 97(3): e45-e47.
Rizos, C. V., M. S. Elisaf and E. N. Liberopoulos (2011). "Effects of thyroid dysfunction on lipid profile." Open Cardiovasc Med J 5: 76-84.
Romere, C., C. Duerrschmid, J. Bournat, P. Constable, M. Jain, F. Xia, P. K. Saha, M. Del Solar, B. Zhu, B. York, P. Sarkar, D. A. Rendon, M. W. Gaber, S. A. LeMaire, J. S. Coselli, D. M. Milewicz, V. R. Sutton, N. F. Butte, D. D. Moore and A. R. Chopra (2016). "Asprosin, a Fasting-Induced Glucogenic Protein Hormone." Cell 165(3): 566-579.
Stefanowicz-Rutkowska, M., A. Baranowska-Jurkun, W. Matuszewski and E. Bandurska-Stankiewicz (2020). "Thyroid dysfunction in patients with diabetic retinopathy." Endokrynologia Polska 71(2): 176-183.
Trayhurn, P. and J. H. Beattie (2001). "Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ." Proc Nutr Soc 60(3): 329-339.
Wang, W. and A. C. Y. Lo (2018). "Diabetic Retinopathy: Pathophysiology and Treatments." Int J Mol Sci 19(6).
Yang, J.-K., W. Liu, J. Shi and Y.-B. Li (2010). "An Association Between Subclinical Hypothyroidism and Sight-Threatening Diabetic Retinopathy in Type 2 Diabetic Patients." Diabetes Care 33(5): 1018-1020.
Yardim, M., F. Celik, Y. Oruc, D. Kayalp, O. Beyazyildiz, D. C. Yesilirmak, M. Ulas and S. Aydin (2022). "Serum asprosin levels in patients with retinopathy of prematurity." Turkish Journal of Biochemistry.
Zhang, X., H. Jiang, X. Ma and H. Wu (2020). "Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus." J Diabetes Investig 11(2): 349-355.
Zhang, X., J. B. Saaddine, C.-F. Chou, M. F. Cotch, Y. J. Cheng, L. S. Geiss, E. W. Gregg, A. L. Albright, B. E. Klein and R. Klein (2010). "Prevalence of diabetic retinopathy in the United States, 2005-2008." Jama 304(6): 649-656.
Zheng, Y., M. He and N. Congdon (2012). "The worldwide epidemic of diabetic retinopathy." Indian journal of ophthalmology 60(5): 428.
Zou, J., Z. Li, F. Tian, Y. Zhang, C. Xu, J. Zhai, M. Shi, G. Wu, Z. Zhang, C. Yang, H. Chen and X. Li (2020). "Association between Normal Thyroid Hormones and Diabetic Retinopathy in Patients with Type 2 Diabetes." BioMed Research International 2020: 8161797
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
